Table 1. Overview of patient biomarker and clinical data.
| Patient ID | Age at diagnosis |
Tumour time-point 1 |
Tumour time-point 2 |
LDT | First treatment (response) | Treatment at relapse (response) | Current status at last follow-up (03/8/15) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGHV (% identity) | FISH/karyo | %CD38 expression | Lymphocyte count (x10^9/L) | IGHV (% identity) | FISH/karyo | %CD38 expression | Lymphocyte count (x10^9/L) | ||||||
| 1 | 52 | IGHV4–61 (93) | del(13q) +/− (54%) | 2 | 6 | IGHV4–61 (93) | del(13q) +/−,−/− (10, 85%) | 1 | 142 | > 1year | – | – | Stable CLL |
| 2 | 72 | IGHV3–73 (91) | del(13q) 46, XY, der4(4)t(4;12)(q35;q13) | 1 | 5 | IGHV3–73 (91) | No change | 1 | 25 | > 1year | – | – | Stable CLL |
| 3 | 57 | IGHV2–70 (93) | del(13q) +/− (90%) | 1 | 92 | IGHV2–70 (93) | No change | 1 | 88 | > 1year | – | – | Stable CLL |
| 4 | 61 | IGHV4–59 (89) | del(13q) +/− (6%) 45, X-Y, t(7,13)(a11.2;q14) | 15 | 34 | IGHV4–59 (89) | del(13q) +/−,−/− (76, 8%), 45, X –Y, t(7;13)(q11.2;q14) | 50 | 136 | > 1year | BR (CR) | – | High-risk MDS. Died. |
| 5 | 79 | IGHV4–61 (92) | del(13q) +/−,−/− (9/86%) 46, XY, t(6;13)(q26;q14) | 1 | 107 | IGHV4–61 (92) | del(13q) +/−,−/− (14/86%) 46, XY, t(6;13)(q26;q14) | – | 198 | > 1year | Chlor (CR) | BR (PR) | Stable CLL |
| 6 | 70 | IGHV3–48 (97) | del(13q) +/− (88%) | 1 | 20 | IGHV3–48 (97) | del(13q) +/−,−/− (53, 10%) | 2 | 127 | 6–12 months | Chlor (GR) | BR (CR) | In remission |
| 7 | 47 | IGHV4–34 (92) | del(13q) +/−,−/− (19, 72%) | 6 | 59 | IGHV4–34 (92) | No change | 1 | 81 | > 1year | Chlor R (PR) | Alemtuz (CR, MRD +ve) | In remission |
| 8 | 59 | IGHV3–23 (96) | Normal | 3 | 21 | IGHV3–23 (96) | del(13q) +/− (66%) 46, XY, del(9)(q21), t(12;15)(p11;q15) | 1 | 48 | > 1year | Chlor Of (CR) | – | In remission |
| 9 | 74 | IGHV3–7 (89) | del(13q) +/− (54%) | 1 | 17 | IGHV3–7 (89) | del(13q) +/− (91%) (+ del17p at TP3) | 1 | 185 | 6–12 months | Chlor (PR) | BR (CR) | On Ibrutinib |
| 10 | 56 | IGHV3–48 (93) | Normal | 5 | 181 | IGHV3–48 (93) | No change | 2 | 139 | > 1year | Chlor (PR) | Continuum | Stable CLL |
| 11 | 64 | IGHV3–23 (91) | 46, XY. No 13q FISH | 1 | 58 | IGHV3–23 (91) | NT | 1 | 145 | > 1year | B Of (CR) | – | In remission |
| 12 | 63 | IGHV4–34 (96) | 47, XY,+12. No 13q FISH | 1 | 42 | IGHV4–34 (96) | NT | 1 | 77 | 6–12 months | Chlor R (CR) | BR (CR, MRD +ve) Continuum | In remission |
| 13 | 67 | IGHV3–48 (92) | Tri 12 (2%) del(13q) −/− (55%) | 9 | 18 | IGHV3–48 (92) & IGHV5-10-1*01 (100) | Tri 12 (73%) (Tri 12 (75%) at TP3) | 21 | 158 | > 1year | Chlor (NR) | BR (PR), Of (PR) | Richters syndrome, NR to CHOP of. Died. |
Abbreviations: BR, bendamustine plus rituximab; FISH, fluorescence in situ hybridisation; LDT, lymphocyte doubling time (from diagnosis for the first year of follow-up); NT, not tested.